Carbohydrate-mimetic peptides for pan anti-tumor responses

Frontiers in Immunology

Volumn 5, Issue JUN, 2014, Pages

  Kieber Emmons, Thomas ^a   Saha, Somdutta ^a   Pashov, Anastas ^b   Monzavi Karbassi, Behjatolah ^a   Murali, Ramachandran ^c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b INSTITUTE OF MICROBIOLOGY   (Bulgaria)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Cancer; Carbohydrate mimetic peptide; Glycans; Mimotope; Structural design; Vaccines

Indexed keywords

EID: 84905653341     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00308     Document Type: Review

References (122)

1. Hakomori S. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol (2001) 491:369-402. doi: 10.1007/978-1-4615-1267-7_24
2. Dong H, Dai H, Hu X, Xiong SD, Gao XM. The (1 →6)-beta-glucan moiety represents a cross-reactive epitope of infection-induced malignancy surveillance. J Immunol (2014) 192:1302-12. doi:10.4049/jimmunol.1301495
3. Collins PM, Bum-Erdene K, Yu X, Blanchard H. Galectin-3 interactions with glycosphingolipids. J Mol Biol (2014) 426:1439-51. doi:10.1016/j.jmb.2013.1412.1004
4. Ragupathi G. Carbohydrate antigens as targets for active specific immunotherapy. Cancer Immunol Immunother (1996) 43:152-7. doi:10.1007/s002620050316
5. Tsai CM. Molecular mimicry of host structures by lipooligosaccharides of Neisseria meningitidis: characterization of sialylated and nonsialylated lacto-N-neotetraose (Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc) structures in lipooligosaccharides using monoclonal antibodies and specific lectins. Adv Exp Med Biol (2001) 491:525-42.
6. Mandrell RE. Further antigenic similarities of Neisseria gonorrhoeae lipooligosaccharides and human glycosphingolipids. Infect Immun (1992) 60:3017-20.
7. Braun JM, Beuth J, Blackwell CC, Giersen S, Higgins PG, Tzanakaki G, et al. Neisseria meningitidis, Neisseria lactamica and Moraxella catarrhalis share cross-reactive carbohydrate antigens. Vaccine (2004) 22:898-908. doi:10.1016/j.vaccine.2003.11.036
8. Ragupathi G, Liu NX, Musselli C, Powell S, Lloyd K, Livingston PO. Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity. J Immunol (2005) 174:5706-12. doi:10.4049/jimmunol.174.9.5706
9. Farhan H, Schuster C, Klinger M, Weisz E, Waxenecker G, Schuster M, et al. Inhibition of xenograft tumor growth and down-regulation of ErbB receptors by an antibody directed against Lewis Y antigen. J Pharmacol Exp Ther (2006) 319:1459-66. doi:10.1124/jpet.106.107318
10. Doronin II, Vishnyakova PA, Kholodenko IV, Ponomarev ED, Ryazantsev DY, Molotkovskaya IM, et al. Ganglioside GD2 in reception and transduction of cell death signal in tumor cells. BMC Cancer (2014) 14:295. doi:10.1186/1471-2407-1114-1295
11. Guo Z, Wang Q. Recent development in carbohydrate-based cancer vaccines. Curr Opin Chem Biol (2009) 13:608-17. doi:10.1016/j.cbpa.2009.08.010
12. Monzavi-Karbassi B, Cunto-Amesty G, Luo P, Kieber-Emmons T. Peptide mimotopes as surrogate antigens of carbohydrates in vaccine discovery. Trends Biotechnol (2002) 20:207-14. doi:10.1016/S0167-7799(02)01940-6
13. Clement MJ, Fortune A, Phalipon A, Marcel-Peyre V, Simenel C, Imberty A, et al. Toward a better understanding of the basis of the molecular mimicry of polysaccharide antigens by peptides: the example of Shigella flexneri 5a. J Biol Chem (2006) 281:2317-32. doi:10.1074/jbc.M510172200
14. Johnson MA, Pinto BM. Structural and functional studies of peptide-carbohydrate mimicry. Top Curr Chem (2008) 273:55-116. doi:10.1007/1128_2007_1018
15. Agostino M, Sandrin MS, Thompson PE, Farrugia W, Ramsland PA, Yuriev E. Carbohydrate-mimetic peptides: structural aspects of mimicry and therapeutic implications. Expert Opin Biol Ther (2011) 11:211-24. doi:10.1517/14712598.14712011.14542140
16. Oldenburg KR, Loganathan D, Goldstein IJ, Schultz PG, Gallop MA. Peptide ligands for a sugar-binding protein isolated from a random peptide library. Proc Natl Acad Sci U S A (1992) 89:5393-7. doi:10.1073/pnas.89.12.5393
17. Scott JK, Loganathan D, Easley RB, Gong X, Goldstein IJ. A family of concanavalin A-binding peptides from a hexapeptide epitope library. Proc Natl Acad Sci U S A (1992) 89:5398-402. doi:10.1073/pnas.89.12.5398
18. Westerink MA, Giardina PC, Apicella MA, Kieber-Emmons T. Peptide mimicry of the meningococcal group C capsular polysaccharide. Proc Natl Acad Sci U S A (1995) 92:4021-5. doi:10.1073/pnas.92.9.4021
19. Agadjanyan M, Luo P, Westerink MA, Carey LA, Hutchins W, Steplewski Z, et al. Peptide mimicry of carbohydrate epitopes on human immunodeficiency virus. Nat Biotechnol (1997) 15:547-51. doi:10.1038/nbt0697-547
20. Kieber-Emmons T, Luo P, Qiu J, Chang TY, O I, Blaszczyk-Thurin M, et al. Vaccination with carbohydrate peptide mimotopes promotes anti-tumor responses. Nat Biotechnol (1999) 17:660-5. doi:10.1038/10870
21. Cunto-Amesty G, Dam TK, Luo P, Monzavi-Karbassi B, Brewer CF, Van Cott TC, et al. Directing the immune response to carbohydrate antigens. J Biol Chem (2001) 276:30490-8. doi:10.1074/jbc.M103257200
22. Melzer H, Baier K, Felici F, Von Specht BU, Wiedermann G, Kollaritsch H, et al. Humoral immune response against proteophosphoglycan surface antigens of Entamoeba histolytica elicited by immunization with synthetic mimotope peptides. FEMS Immunol Med Microbiol (2003) 37:179-83. doi:10.1016/S0928-8244(03)00074-9
23. Maitta RW, Datta K, Lees A, Belouski SS, Pirofski LA. Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice. Infect Immun (2004) 72:196-208. doi:10.1128/IAI.72.1.196-208.2004
24. Park I, Choi IH, Kim SJ, Shin JS. Peptide mimotopes of Neisseria meningitidis group B capsular polysaccharide. Yonsei Med J (2004) 45:755-8.
25. Prinz DM, Smithson SL, Westerink MA. Two different methods result in the selection of peptides that induce a protective antibody response to Neisseria meningitidis serogroup C. J Immunol Methods (2004) 285:1-14. doi:10.1016/j.jim.2003.08.005
26. Buchwald UK, Lees A, Steinitz M, Pirofski LA. A peptide mimotope of type 8 pneumococcal capsular polysaccharide induces a protective immune response in mice. Infect Immun (2005) 73:325-33. doi:10.1128/IAI.73.1.325-333.2005
27. Monzavi-Karbassi B, Shamloo S, Kieber-Emmons M, Jousheghany F, Luo P, Lin KY, et al. Priming characteristics of peptide mimotopes of carbohydrate antigens. Vaccine (2003) 21:753-60. doi:10.1016/S0264-410X(02)00703-X
28. Luo P, Canziani G, Cunto-Amesty G, Kieber-Emmons T. A molecular basis for functional peptide mimicry of a carbohydrate antigen. J Biol Chem (2000) 275:16146-54. doi:10.1074/jbc.M909121199
29. Monzavi-Karbassi B, Hennings LJ, Artaud C, Liu T, Jousheghany F, Pashov A, et al. Preclinical studies of carbohydrate mimetic peptide vaccines for breast cancer and melanoma. Vaccine (2007) 25:3022-31. doi:10.1016/j.vaccine.2007.01.072
30. Van Regenmortel MH. Transcending the structuralist paradigm in immunology-affinity and biological activity rather than purely structural considerations should guide the design of synthetic peptide epitopes. Biomed Pept Proteins Nucleic Acids (1995) 1:109-16.
31. Van Regenmortel MH. Molecular design versus empirical discovery in peptide-based vaccines. Coming to terms with fuzzy recognition sites and ill-defined structure-function relationships in immunology. Vaccine (1999) 18:216-21. doi:10.1016/S0264-410X(99)00192-9
32. Van Regenmortel MH. Antigenicity and immunogenicity of synthetic peptides. Biologicals (2001) 29:209-13. doi:10.1006/biol.2001.0308
33. Oldstone MB. Molecular mimicry: its evolution from concept to mechanism as a cause of autoimmune diseases. Monoclon Antib Immunodiagn Immunother (2014) 2:2. doi:10.1089/mab.2013.0090
34. Kieber-Emmons T, Monzavi-Karbassi B, Pashov A, Saha S, Murali R, Kohler H. The promise of the anti-idiotype concept. Front Oncol (2012) 2:196. doi:10.3389/fonc.2012.00196
35. Jacobsen JT, Lunde E, Sundvold-Gjerstad V, Munthe LA, Bogen B. The cellular mechanism by which complementary Id+ and anti-Id antibodies communicate: T cells integrated into idiotypic regulation. Immunol Cell Biol (2010) 88:515-22. doi:10.1038/icb.2009.118
36. Foon KA, Lutzky J, Baral RN, Yannelli JR, Hutchins L, Teitelbaum A, et al. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J Clin Oncol (2000) 18:376-84.
37. Chapman PB. Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody. Curr Opin Investig Drugs (2003) 4:710-5.
38. Chapman PB, Wu D, Ragupathi G, Lu S, Williams L, Hwu WJ, et al. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside. Clin Cancer Res (2004) 10:4717-23. doi:10.1158/1078-0432.CCR-04-0345
39. Alfonso S, Diaz RM, De La Torre A, Santiesteban E, Aguirre F, Perez K, et al. 1E10 anti-idiotype vaccine in non-small cell lung cancer: experience in stage IIIB/IV patients. Cancer Biol Ther (2007) 6:1847-52. doi:10.4161/cbt.6.12.5000
40. Fernandez LE, Gabri MR, Guthmann MD, Gomez RE, Gold S, Fainboim L, et al. NGcGM3 ganglioside: a privileged target for cancer vaccines. Clin Dev Immunol (2010) 2010:814397. doi:10.1155/2010/814397
41. Hoffmuller U, Knaute T, Hahn M, Hohne W, Schneider-Mergener J, Kramer A. Evolutionary transition pathways for changing peptide ligand specificity and structure. EMBO J (2000) 19:4866-74. doi:10.1093/emboj/19.18.4866
42. Coletta A, Pinney JW, Solis DY, Marsh J, Pettifer SR, Attwood TK. Low-complexity regions within protein sequences have position-dependent roles. BMC Syst Biol (2010) 4:43. doi:10.1186/1752-0509-1184-1143
43. Bonsor DA, Grishkovskaya I, Dodson EJ, Kleanthous C. Molecular mimicry enables competitive recruitment by a natively disordered protein. J Am Chem Soc (2007) 129:4800-7. doi:10.1021/ja070153n
44. Notkins AL. Polyreactivity of antibody molecules. Trends Immunol (2004) 25:174-9. doi:10.1016/j.it.2004.02.004
45. Atlan H, Cohen IR. Immune information, self-organization and meaning. Int Immunol (1998) 10:711-7. doi:10.1093/intimm/10.6.711
46. Mason D. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol Today (1998) 19:395-404. doi:10.1016/S0167-5699(98)01299-7
47. Dimitrov JD, Ivanovska ND, Lacroix-Desmazes S, Doltchinkova VR, Kaveri SV, Vassilev TL. Ferrous ions and reactive oxygen species increase antigen-binding and anti-inflammatory activities of immunoglobulin G. J Biol Chem (2006) 281:439-46. doi:10.1074/jbc.M509190200
48. McIntyre JA, Faulk WP. Redox-reactive autoantibodies: biochemistry, characterization, and specificities. Clin Rev Allergy Immunol (2009) 37:49-54. doi:10.1007/s12016-008-8093-y
49. Dimitrov JD, Pashov A, Vassilev T. Antibody polyspecificity: what does it matter? In: Lutz HU, editor. Naturally Occurring Antibodies (NAbs). Austin, TX: Springer (2012). 268 p.
50. Matzinger P. The danger model: a renewed sense of self. Science (2002) 296:301-5. doi:10.1126/science.1071059
51. Medzhitov R, Janeway CA Jr. Decoding the patterns of self and nonself by the innate immune system. Science (2002) 296:298-300. doi:10.1126/science.1068883
52. Forrest S, Javornik B, Smith RE, Perelson AS. Using genetic algorithms to explore pattern recognition in the immune system. Evol Comput (1993) 1:191-211. doi:10.1162/evco.1993.1.3.191
53. Kearney JF. Immune recognition of OxLDL in atherosclerosis. J Clin Invest (2000) 105:1683-5. doi:10.1172/JCI10426
54. Roozendaal R, Carroll MC. Emerging patterns in complement-mediated pathogen recognition. Cell (2006) 125:29-32. doi:10.1016/j.cell.2006.03.018
55. Quinn A, Adderson EE, Shackelford PG, Carroll WL, Cunningham MW. Autoantibody germ-line gene segment encodes VH and VL regions of a human anti-streptococcal monoclonal antibody recognizing streptococcal M protein and human cardiac myosin epitopes. J Immunol (1995) 154:4203-12.
56. Apostolopoulos V, Osinski C, Mckenzie IF. MUC1 cross-reactive Gal alpha(1,3)Gal antibodies in humans switch immune responses from cellular to humoral. Nat Med (1998) 4:315-20. doi:10.1038/nm0398-315
57. Pashov A, Canziani G, Macleod S, Plaxco J, Monzavi-Karbassi B, Kieber-Emmons T. Targeting carbohydrate antigens in HIV vaccine development. Vaccine (2005) 23:2168-75. doi:10.1016/j.vaccine.2005.01.045
58. Moore CJ, Auzanneau FI. Understanding the recognition of Lewis X by anti-Le(x) monoclonal antibodies. J Med Chem (2013) 56:8183-90. doi:10.1021/jm401304h
59. Yang L, Adam C, Nichol GS, Cockroft SL. How much do van der Waals dispersion forces contribute to molecular recognition in solution? Nat Chem (2013) 5:1006-10. doi:10.1038/nchem.1779
60. Bostrom J, Haber L, Koenig P, Kelley RF, Fuh G. High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity. PLoS One (2011) 6:e17887. doi:10.11371/journal.pone.0017887
61. Riemer AB, Jensen-Jarolim E. Mimotope vaccines: epitope mimics induce anti-cancer antibodies. Immunol Lett (2007) 113:1-5. doi:10.1016/j.imlet.2007.07.008
62. Cunto-Amesty G, Luo P, Monzavi-Karbassi B, Lees A, Kieber-Emmons T. Exploiting molecular mimicry to broaden the immune response to carbohydrate antigens for vaccine development. Vaccine (2001) 19:2361-8. doi:10.1016/S0264-410X(00)00527-2
63. Monzavi-Karbassi B, Cunto-Amesty G, Luo P, Shamloo S, Blaszcyk-Thurin M, Kieber-Emmons T. Immunization with a carbohydrate mimicking peptide augments tumor-specific cellular responses. Int Immunol (2001) 13:1361-71. doi:10.1093/intimm/13.11.1361
64. Hennings L, Artaud C, Jousheghany F, Monzavi-Karbassi B, Pashov A, Kieber-Emmons T. Carbohydrate mimetic peptides augment carbohydrate-reactive immune responses in the absence of immune pathology. Cancers (Basel) (2011) 3:4151-69. doi:10.3390/cancers3044151
65. Grothaus MC, Srivastava N, Smithson SL, Kieber-Emmons T, Williams DB, Carlone GM, et al. Selection of an immunogenic peptide mimic of the capsular polysaccharide of Neisseria meningitidis serogroup A using a peptide display library. Vaccine (2000) 18:1253-63. doi:10.1016/S0264-410X(99)00390-4
66. Fleuridor R, Lees A, Pirofski L. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection. J Immunol (2001) 166:1087-96. doi:10.4049/jimmunol.166.2.1087
67. Cunto-Amesty G, Luo P, Monzavi-Karbassi B, Lees A, Alexander J, Del Guercio MF, et al. Peptide mimotopes as prototypic templates of broad-spectrum surrogates of carbohydrate antigens. Cell Mol Biol (Noisy-le-grand) (2003) 49:245-54.
68. Haurum JS, Arsequell G, Lellouch AC, Wong SY, Dwek RA, Mcmichael AJ, et al. Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes. J Exp Med (1994) 180:739-44. doi:10.1084/jem.180.2.739
69. Jensen T, Galli-Stampino L, Mouritsen S, Frische K, Peters S, Meldal M, et al. T cell recognition of Tn-glycosylated peptide antigens. Eur J Immunol (1996) 26:1342-9. doi:10.1002/eji.1830260625
70. Galli-Stampino L, Meinjohanns E, Frische K, Meldal M, Jensen T, Werdelin O, et al. T-cell recognition of tumor-associated carbohydrates: the nature of the glycan moiety plays a decisive role in determining glycopeptide immunogenicity. Cancer Res (1997) 57:3214-22.
71. Zhao XJ, Cheung NK. GD2 oligosaccharide: target for cytotoxic T lymphocytes. J Exp Med (1995) 182:67-74. doi:10.1084/jem.182.1.67
72. Glithero A, Tormo J, Haurum JS, Arsequell G, Valencia G, Edwards J, et al. Crystal structures of two H-2Db/glycopeptide complexes suggest a molecular basis for CTL cross-reactivity. Immunity (1999) 10:63-74. doi:10.1016/S1074-7613(00)80007-2
73. Speir JA, Abdel-Motal UM, Jondal M, Wilson IA. Crystal structure of an MHC class I presented glycopeptide that generates carbohydrate-specific CTL. Immunity (1999) 10:51-61. doi:10.1016/S1074-7613(00)80006-0
74. Abdel-Motal UM, Berg L, Rosen A, Bengtsson M, Thorpe CJ, Kihlberg J, et al. Immunization with glycosylated Kb-binding peptides generates carbohydrate-specific, unrestricted cytotoxic T cells. Eur J Immunol (1996) 26:544-51. doi:10.1002/eji.1830260307
75. Tzianabos AO, Finberg RW, Wang Y, Chan M, Onderdonk AB, Jennings HJ, et al. T cells activated by zwitterionic molecules prevent abscesses induced by pathogenic bacteria. J Biol Chem (2000) 275:6733-40. doi:10.1074/jbc.275.10.6733
76. Kieber-Emmons T, Monzavi-Karbassi B, Wang B, Luo P, Weiner DB. Cutting edge: DNA immunization with minigenes of carbohydrate mimotopes induce functional anti-carbohydrate antibody response. J Immunol (2000) 165:623-7. doi:10.4049/jimmunol.165.2.623
77. Monzavi-Karbassi B, Luo P, Jousheghany F, Torres-Quinones M, Cunto-Amesty G, Artaud C, et al. A mimic of tumor rejection antigen-associated carbohydrates mediates an antitumor cellular response. Cancer Res (2004) 64:2162-6. doi:10.1158/0008-5472.CAN-03-1532
78. Harris SL, Dagtas AS, Diamond B. Regulating the isotypic and idiotypic profile of an anti-PC antibody response: lessons from peptide mimics. Mol Immunol (2002) 39:263-72. doi:10.1016/S0161-5890(02)00116-5
79. Talavera A, Eriksson A, Okvist M, Lopez-Requena A, Fernandez-Marrero Y, Perez R, et al. Crystal structure of an anti-ganglioside antibody, and modelling of the functional mimicry of its NeuGc-GM3 antigen by an anti-idiotypic antibody. Mol Immunol (2009) 46:3466-75. doi:10.1016/j.molimm.2009.3407.3032
80. Monzavi-Karbassi B, Artaud C, Jousheghany F, Hennings L, Carcel-Trullols J, Shaaf S, et al. Reduction of spontaneous metastases through induction of carbohydrate cross-reactive apoptotic antibodies. J Immunol (2005) 174:7057-65. doi:10.4049/jimmunol.174.11.7057
81. Vollmers HP, Brandlein S. Death by stress: natural IgM-induced apoptosis. Methods Find Exp Clin Pharmacol (2005) 27:185-91. doi:10.1358/mf.2005.27.3.890876
82. Vollmers HP, Brandlein S. Natural antibodies and cancer. N Biotechnol (2009) 25:294-8. doi:10.1016/j.nbt.2009.03.016
83. Hoess R, Brinkmann U, Handel T, Pastan I. Identification of a peptide which binds to the carbohydrate-specific monoclonal antibody B3. Gene (1993) 128:43-9. doi:10.1016/0378-1119(93)90151-R
84. Jain D, Kaur KJ, Salunke DM. Enhanced binding of a rationally designed peptide ligand of concanavalin a arises from improved geometrical complementarity. Biochemistry (2001) 40:12059-66. doi:10.1021/bi011254f
85. Pashov A, Perry M, Dyar M, Chow M, Kieber-Emmons T. Carbohydrate mimotopes in the rational design of cancer vaccines. Curr Top Med Chem (2005) 5:1171-85. doi:10.2174/156802605774370928
86. Pashov A, Perry M, Dyar M, Chow M, Kieber-Emmons T. Defining carbohydrate antigens as HIV vaccine candidates. Curr Pharm Des (2007) 13:185-201. doi:10.2174/138161207779313678
87. Agostino M, Sandrin MS, Thompson PE, Ramsland PA, Yuriev E. Peptide inhibitors of xenoreactive antibodies mimic the interaction profile of the native carbohydrate antigens. Biopolymers (2011) 96:193-206. doi:10.1002/bip.21427
88. Agostino M, Yuriev E, Ramsland PA. Antibody recognition of cancer-related gangliosides and their mimics investigated using in silico site mapping. PLoS One (2012) 7:e35457. doi:10.31371/journal.pone.0035457
89. Qiu J, Luo P, Wasmund K, Steplewski Z, Kieber-Emmons T. Towards the development of peptide mimotopes of carbohydrate antigens as cancer vaccines. Hybridoma (1999) 18:103-12. doi:10.1089/hyb.1999.18.103
90. Wondimu A, Zhang T, Kieber-Emmons T, Gimotty P, Sproesser K, Somasundaram R, et al. Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice. Cancer Immunol Immunother (2008) 57:1079-89. doi:10.1007/s00262-007-0439-4
91. Hurwitz AA, Ji Q. Autoimmune depigmentation following sensitization to melanoma antigens. Methods Mol Med (2004) 102:421-7.
92. Galili U. Anti-Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits. Immunology (2013) 140:1-11. doi:10.1111/imm.12110
93. Preiss S, Kammertoens T, Lampert C, Willimsky G, Blankenstein T. Tumor-induced antibodies resemble the response to tissue damage. Int J Cancer (2005) 115:456-62. doi:10.1002/ijc.20914
94. Kirkeby S, Moe D. Lectin interactions with alpha-galactosylated xenoantigens. Xenotransplantation (2002) 9:260-7. doi:10.1034/j.1399-3089.2002.01078.x
95. Korourian S, Siegel E, Kieber-Emmons T, Monzavi-Karbassi B. Expression analysis of carbohydrate antigens in ductal carcinoma in situ of the breast by lectin histochemistry. BMC Cancer (2008) 8:136. doi:10.1186/1471-2407-1188-1136
96. Zuckier LS, Berkowitz EZ, Sattenberg RJ, Zhao QH, Deng HF, Scharff MD. Influence of affinity and antigen density on antibody localization in a modifiable tumor targeting model. Cancer Res (2000) 60:7008-13.
97. Takahashi T, Johnson TD, Nishinaka Y, Morton DL, Irie RF. IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients. J Invest Dermatol (1999) 112:205-9. doi:10.1046/j.1523-1747.1999.00493.x
98. Hermsen BB, Verheijen RH, Menko FH, Gille JJ, Van Uffelen K, Blankenstein MA, et al. Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation. Eur J Cancer (2007) 43:1556-63. doi:10.1016/j.ejca.2007.04.007
99. Amigorena S. Fc gamma receptors and cross-presentation in dendritic cells. J Exp Med (2002) 195:F1-3. doi:10.1084/jem.20011925
100. Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med (2002) 195:125-33. doi:10.1084/jem.20011097
101. Wernersson S, Kleinau S, Heyman B. Immune complex-mediated enhancement of antibody responses without induction of delayed-type hypersensitivity. Scand J Immunol (2000) 52:563-9. doi:10.1046/j.1365-3083.2000.00813.x
102. Forster-Waldl E, Riemer AB, Dehof AK, Neumann D, Bramswig K, Boltz-Nitulescu G, et al. Isolation and structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor antigen. Mol Immunol (2005) 42:319-25. doi:10.1016/j.molimm.2004.07.011
103. Riemer AB, Forster-Waldl E, Bramswig KH, Pollak A, Zielinski CC, Pehamberger H, et al. Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes. Eur J Immunol (2006) 36:1267-74. doi:10.1002/eji.200535279
104. Horwacik I, Czaplicki D, Talarek K, Kowalczyk A, Bolesta E, Kozbor D, et al. Selection of novel peptide mimics of the GD2 ganglioside from a constrained phage-displayed peptide library. Int J Mol Med (2007) 19:829-39.
105. Horwacik I, Kurcinski M, Bzowska M, Kowalczyk AK, Czaplicki D, Kolinski A, et al. Analysis and optimization of interactions between peptides mimicking the GD2 ganglioside and the monoclonal antibody 14G2a. Int J Mol Med (2011) 28:47-57. doi:10.3892/ijmm.2011.3655
106. Willers J, Lucchese A, Kanduc D, Ferrone S. Molecular mimicry of phage displayed peptides mimicking GD3 ganglioside. Peptides (1999) 20:1021-6. doi:10.1016/S0196-9781(99)00095-9
107. O I, Kieber-Emmons T, Otvos L Jr, Blaszczyk-Thurin M. Peptides mimicking sialyl-Lewis A isolated from a random peptide library and peptide array. Ann N Y Acad Sci (1999) 886:276-9. doi:10.1111/j.1749-6632.1999.tb09435.x
108. Foon KA, Sen G, Hutchins L, Kashala OL, Baral R, Banerjee M, et al. Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. Clin Cancer Res (1998) 4:1117-24.
109. Cheung NK, Guo HF, Heller G, Cheung IY. Induction of Ab3 and Ab3′ antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma. Clin Cancer Res (2000) 6:2653-60.
110. Zeytin HE, Tripathi PK, Bhattacharya-Chatterjee M, Foon KA, Chatterjee SK. Construction and characterization of DNA vaccines encoding the single-chain variable fragment of the anti-idiotype antibody 1A7 mimicking the tumor-associated antigen disialoganglioside GD2. Cancer Gene Ther (2000) 7:1426-36. doi:10.1038/sj.cgt.7700240
111. Lode HN, Schmidt M, Seidel D, Huebener N, Brackrock D, Bleeke M, et al. Vaccination with anti-idiotype antibody ganglidiomab mediates a GD(2)-specific anti-neuroblastoma immune response. Cancer Immunol Immunother (2013) 62:999-1010. doi:10.1007/s00262-00013-01413-y
112. Bottomley A, Debruyne C, Felip E, Millward M, Thiberville L, D'Addario G, et al. Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer. Eur J Cancer (2008) 44:2178-84. doi:10.1016/j.ejca.2008.2106.2036
113. Hernandez AM, Rodriguez N, Gonzalez JE, Reyes E, Rondon T, Grinan T, et al. Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism. J Immunol (2011) 186:3735-44. doi:10.4049/jimmunol.1000609
114. Hernandez AM, Toledo D, Martinez D, Grinan T, Brito V, Macias A, et al. Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. J Immunol (2008) 181:6625-34. doi:10.4049/jimmunol.181.9.6625
115. Chapman PB, Williams L, Salibi N, Hwu WJ, Krown SE, Livingston PO. A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside. Vaccine (2004) 22:2904-9. doi:10.1016/j.vaccine.2003.12.028
116. McCaffery M, Yao TJ, Williams L, Livingston PO, Houghton AN, Chapman PB. Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant. Clin Cancer Res (1996) 2:679-86.
117. Vazquez AM, Rodreguez-Zhurbenko N, Lopez AM. Anti-ganglioside anti-idiotypic vaccination: more than molecular mimicry. Front Oncol (2012) 2:170. doi:10.3389/fonc.2012.00170
118. Koehn TA, Trimble LL, Alderson KL, Erbe AK, Mcdowell KA, Grzywacz B, et al. Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma. Front Pharmacol (2012) 3:91. doi:10.3389/fphar.2012.00091
119. Tarek N, Le Luduec JB, Gallagher MM, Zheng J, Venstrom JM, Chamberlain E, et al. Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J Clin Invest (2012) 122:3260-70. doi:10.1172/JCI62749
120. Perez CA, Ravindranath MH, Soh D, Gonzales A, Ye W, Morton DL. Serum anti-ganglioside IgM antibodies in soft tissue sarcoma: clinical prognostic implications. Cancer J (2002) 8:384-94. doi:10.1097/00130404-200209000-00009
121. Ravindranath MH, Muthugounder S, Presser N, Ye X, Brosman S, Morton DL. Endogenous immune response to gangliosides in patients with confined prostate cancer. Int J Cancer (2005) 116:368-77. doi:10.1002/ijc.21023
122. Ravindranath MH, Muthugounder S, Hannah MR, Morton DL. Significance of endogenous augmentation of antiganglioside IgM in cancer patients: potential tool for early detection and management of cancer therapy. Ann N Y Acad Sci (2007) 1107:212-22. doi:10.1196/annals.1381.023